Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 13.9% After Analyst Upgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded up 13.9% during trading on Monday after Wedbush raised their price target on the stock from $32.00 to $34.00. Wedbush currently has an outperform rating on the stock. Sarepta Therapeutics traded as high as $24.46 and last traded at $24.0730. 1,556,026 shares changed hands during mid-day trading, a decline of 47% from the average session volume of 2,936,165 shares. The stock had previously closed at $21.13.

Several other analysts have also recently weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, January 14th. Wells Fargo & Company dropped their price target on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Barclays cut their price objective on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 5th. Finally, Robert W. Baird lowered their target price on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $33.84.

Insiders Place Their Bets

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares in the company, valued at approximately $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.60% of the company’s stock.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company press release and coverage report ELEVIDYS produced statistically significant, clinically meaningful slowing of Duchenne progression at three years in the EMBARK Phase 3 topline results, driving investor optimism about the therapy’s commercial prospects. Sarepta Announces Positive Topline Three-Year EMBARK Results
• Positive Sentiment: Market reaction included an intraday jump noted by Zacks as shares climbed after the long‑term Elevidys data showed sustained motor gains and slower progression at three years. SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
• Positive Sentiment: Major outlets (Reuters, Barron’s, Proactive) reinforced the data’s credibility with independent reporting of the three‑year benefits, supporting near‑term sentiment and potential uptake. Reuters: Sarepta’s Duchenne gene therapy helps maintain motor function
• Positive Sentiment: Zacks upgraded SRPT to a Buy, signaling growing optimism from some sell‑side analysts that the data improves earnings prospects and valuation upside. Sarepta Therapeutics (SRPT) Upgraded to Buy
• Neutral Sentiment: Seeking Alpha published slides and a transcript of Sarepta’s EMBARK presentation — useful for investors wanting the detailed endpoints, subgroup analyses and methodology. Seeking Alpha: EMBARK 3‑Year Results Slides/Transcript
• Neutral Sentiment: Analysts and outlets are reassessing SRPT valuation after the short‑term momentum; a Yahoo Finance piece looks at valuation upside versus remaining uncertainties. Assessing Sarepta Therapeutics (SRPT) Valuation
• Negative Sentiment: Citi (reported via TipRanks) reiterated a bearish stance, citing safety uncertainty and label risk that they say overshadow the positive Elevidys data and support a Sell/high‑risk rating. TipRanks: Safety Uncertainty and Label Risk Overshadow Elevidys Data
• Negative Sentiment: HC Wainwright reaffirmed a Sell rating (reported by Benzinga), signaling that at least some sell‑side firms remain unconvinced and could pressure sentiment. Benzinga: HC Wainwright Reaffirms Sell
• Negative Sentiment: Pre‑existing safety concerns remain relevant: prior FDA restrictions on ELEVIDYS (after liver‑related adverse events in non‑ambulatory patients) are cited in coverage and underpin continued label and commercial risk. Blockonomi: Investors Brace for Pivotal Data; FDA Restriction Context

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Sarepta Therapeutics by 10.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,454 shares of the biotechnology company’s stock worth $655,000 after purchasing an additional 2,954 shares in the last quarter. Krilogy Financial LLC lifted its stake in Sarepta Therapeutics by 164.7% in the fourth quarter. Krilogy Financial LLC now owns 27,982 shares of the biotechnology company’s stock valued at $638,000 after buying an additional 17,409 shares in the last quarter. Lecap Asset Management Ltd. acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $241,000. Merit Financial Group LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $820,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Sarepta Therapeutics by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,092 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 1,068 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Down 2.8%

The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -7.37, a price-to-earnings-growth ratio of 0.56 and a beta of 0.48. The business’s fifty day moving average is $21.32 and its 200 day moving average is $19.86. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.Sarepta Therapeutics’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same quarter last year, the company posted $0.62 EPS. Equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.